Palliative therapeutic control of tumor progression in patients with metastatic breast cancer
Possinger, K.; Wilmanns, W.
Der Internist 34(4): 340-350
1993
ISSN/ISBN: 0020-9554 PMID: 7683634 Document Number: 415916
Document emailed within 1 workday
Related Documents
Yokdang, N.; Buxton, N.D.; Buxton, I.L.O. 2009: Measurement of human breast tumor cell-secreted shNDPK-B in a murine breast cancer model suggests its role in metastatic progression Proceedings of the Western Pharmacology Society 52: 88-91Isono, H.; Kemmoku, T.; Nakamura, Y.; Onose, A.; Matsumoto, Y.; Watanabe, R.; Haraguchi, M.; Kasajima, M.; Takaya, S.; Ishihara, M.; Karigane, D.; Nagata, H. 2011: Early diagnosis of metastatic spinal tumor is a key for effective palliative radiotherapy in patients with lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(Suppl 1): 64-66
Kos, T.; Aksoy, S.; Sendur, M.A.N.; Arik, Z.; Civelek, B.; Kandemir, N.; Ozdemir, N.Y.; Zengin, N.; Altundag, K. 2013: Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes Journal of BUON: Official Journal of the Balkan Union of Oncology 18(3): 608-613
Rosset, G.; Barrelet, L.; Alberto, P. 1975: Palliative treatment of metastatic breast cancer with diethyldioxystilbene diphosphate (Honvan) Schweizerische Medizinische Wochenschrift 105(43): 1388-1390
Schuurman, J.J.; Bong, S.B.; Einarsson, R. 1996: Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients Anticancer Research 16(4b): 2169-2172
Brivio, F.; Fumagalli, L.; Fumagalli, G.; Pescia, S.; Brivio, R.; Di Fede, G.; Rovelli, F.; Lissoni, P. 2010: Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression In Vivo 24(2): 239-241
Pannuti, F.; Rossi, A.P.; Di Marco, A.R.; Fruet, F.; Lelli, G.; Strocchi, E.; Rocchetta, G.; Piana, E.; Martoni, A. 1981: Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot study Panminerva Medica 23(1): 25-28
Murray, J.L.; Macey, D.J.; Grant, E.J.; Rosenblum, M.G.; Kasi, L.P.; Zhang, H.Z.; Katz, R.L.; Riger, P.T.; LeBherz, D.; Bhadkamkar, V. 1995: Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment Cancer Research 55(23 Suppl): 5925s-5928s
Tsunoda, Y.; Tsunoda, A.; Kusano, M.; Tachikawa, T. 2007: Tumor progression and invasion-related genes for breast cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 6): 127-132
Lissoni, P.; Malugani, F.; Brivio, F.; Piazza, A.; Vintimilla, C.; Giani, L.; Tancini, G. 2003: Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase Ii study Neuro Endocrinology Letters 24(3-4): 259-262
Kan, N.; Yoshikawa, K.; Nio, Y.; Iguchi, C.; Kodama, H. 2007: Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(7): 1047-1052
Frost, P.; Kerbel, R.S.; Hunt, B.; Man, S.; Pathak, S. 1987: Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression Cancer Research 47(10): 2690-2695
Bozkurt, O.; Firat, S.Tarik.; Dogan, E.; Cosar, R.; Inanc, M.; Ozkan, M. 2019: The prognostic value of the change in neutrophil-to-lymphocyte ratio during first-line palliative chemotherapy in patients with metastatic gastric cancer: A retrospective study Journal of BUON: Official Journal of the Balkan Union of Oncology 24(5): 1992-1999
Mombello, A.; Mariuzzi, L.; Morelli, L.; Granchelli, G.; Rucco, V.; Tarocco, E.; da Silva, V.D.; Thompson, D.; Bartels, H.G.; Bartels, P.H.; Mariuzzi, G. 2001: Quantitative study of ductal breast cancer progression: nuclear signatures for evaluation of progression grade Advances in Clinical Pathology: the Official Journal of Adriatic Society of Pathology 5(3): 59-70
Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. 2007: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone Anticancer Research 27(3b): 1519-1525
Zieglschmid, V.; Hollmann, C.; Mannel, J.; Albert, W.; Jaeschke-Melli, S.; Eckstein, B.; Hillemann, T.; Greten, T.F.; Gross, E.; Böcher, O. 2007: Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer Anticancer Research 27(4a): 1823-1832
Mariuzzi, L.; Mombello, A.; Rucco, V.; Morelli, L.; Zamò, A.; Thompson, D.; Vaught, L.; Bartels, H.G.; Mariuzzi, G.; Bartels, P.H. 2000: Quantitative study of ductal breast cancer progression: signatures of nuclei in proliferating breast lesions and in situ cancer Advances in Clinical Pathology: the Official Journal of Adriatic Society of Pathology 4(2): 87-97
Lundin, A.C.; Söderkvist, P.; Eriksson, B.; Bergman-Jungeström, M.; Wingren, S. 1999: Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group Cancer Research 59(10): 2332-2334
Balázs, M.; Tüske, M. 1986: Polychemotherapeutic treatment of patients with metastatic breast cancer Acta Medica Hungarica 43(4): 407-411
Chagpar, A.B. 2007: Insights into the management of locally advanced, inflammatory, and metastatic breast cancer: highlights from the 2007 Louisville Breast Cancer Update Journal of the Kentucky Medical Association 105(11): 559-560